FDA Approved New Treatment for Resistant Herpes Lesions
The drug Hovilpri offers a new option for immunocompromised adults with lesions that do not respond to standard antivirals.
Updated on Oct. 9, 2026 in Cancer
Live Poll
Do you trust the FDA's current process for evaluating the safety and effectiveness of new drugs?
The FDA has approved Hovilpri tablets to treat mucocutaneous lesions caused by the herpes simplex virus in immunocompromised adults. The medication is specifically for patients whose lesions have failed to respond to common treatments like acyclovir, valacyclovir, or famciclovir.
Why it matters
Immunocompromised individuals are at high risk for herpes simplex outbreaks that can become resistant to conventional antiviral therapies. This approval provides a needed clinical alternative for patients who previously had few options for healing unresponsive lesions.
In the PRIOH-1 Phase 3 trial involving 101 immunocompromised adults, 63% of patients treated with Hovilpri achieved total lesion healing by 28 days compared to 34% in the comparator arm. The study evaluated patients over a primary 28-day treatment period.
The players
Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and medical devices.
The details
Hovilpri works as an antiviral medication designed to address herpes simplex virus lesions that persist despite treatment with standard nucleoside analogues. During the trial, patients received the drug for up to 28 days, with the possibility of extending administration to 42 days for those demonstrating improvement. The most common side effect reported by participants during the study was headache.
Timeline
- 2026-10-09
FDA approved Hovilpri tablets for clinical use.
Health Landscape
This approval follows the FDA's priority review process, which accelerates the path to market for drugs that provide significant improvements in the safety or effectiveness of treatment. It addresses a specific gap in the current standard of care for patients with drug-resistant viral outbreaks.
If you are immunocompromised and struggling with herpes simplex lesions that have not cleared with standard medications, this treatment may be worth discussing with your doctor. Always consult a physician to review your treatment history and determine if this new option is appropriate for your care.
The takeaway
Hovilpri provides a new path to healing for immunocompromised patients facing resistant herpes simplex lesions. Keep a detailed log of your treatment history and any medications that have failed to work, as this information is essential when speaking with your physician about new care options.
Further reading
Learn more about the latest developments in systemic therapies by visiting our Cancer section.
More information
View the official FDA drug approval announcement for technical details.
Live Poll
Do you trust the FDA's current process for evaluating the safety and effectiveness of new drugs?
